Mechanism of action
Lithium's exact mechanism remains incompletely understood, but it modulates multiple intracellular signaling pathways. The most studied mechanism is inhibition of inositol monophosphatase, which depletes phosphatidylinositol and dampens downstream signaling cascades involved in neuronal excitability.
Lithium also affects:
- Neurotransmitter systems: modulates serotonin, dopamine, and glutamate activity
- Glycogen synthase kinase-3 (GSK-3) inhibition: influences neuroplasticity and neuroprotection
- Second messenger systems: alters cyclic AMP and protein kinase C signaling
- Neuroprotective effects: may increase brain-derived neurotrophic factor (BDNF) and promote neurogenesis
These pleiotropic effects stabilize mood by reducing excessive neuronal excitability during manic episodes and may have antidepressant properties. Lithium competes with sodium, potassium, calcium, and magnesium at various transport and channel sites, contributing to both therapeutic and adverse effects.
- Lithium has a narrow therapeutic index (0.6-1.2 mEq/L); toxicity occurs at >1.5 mEq/L
- Nephrogenic diabetes insipidus is a common side effect; treat with amiloride or thiazides (paradoxical effect)
- Thiazide diuretics increase lithium levels by reducing renal clearance; NSAIDs (except aspirin) also increase levels
- Hypothyroidism occurs in 5-35% of patients; monitor TSH every 6-12 months
- Ebstein anomaly (cardiac malformation) is associated with first-trimester lithium exposure (~0.05-0.1% risk)
- Dehydration and sodium depletion increase lithium reabsorption, raising serum levels and toxicity risk
- Signs of toxicity: coarse tremor, confusion, ataxia, hyperreflexia, dysarthria; severe cases require hemodialysis
- Lithium is the mood stabilizer with the strongest evidence for reducing suicide risk in bipolar disorder
Indications
FDA-approved:
- Acute manic episodes in bipolar I disorder
- Maintenance treatment of bipolar disorder (prevents recurrence of mania and depression)
Off-label uses:
- Augmentation in treatment-resistant major depressive disorder
- Bipolar depression (acute treatment)
- Reduction of suicidal behavior in mood disorders
- Cluster headache prophylaxis
- Aggression and impulse control disorders
Lithium is particularly effective for classic euphoric mania and has the strongest evidence for suicide prevention among mood stabilizers. It may be less effective in rapid-cycling bipolar disorder or mixed episodes compared to valproate or atypical antipsychotics.
Pharmacokinetics
Absorption: Complete oral absorption; peak plasma levels in 1-3 hours (immediate-release) or 4-12 hours (extended-release).
Distribution: Distributes throughout total body water; not protein-bound. Crosses the placenta and enters breast milk. Slowly crosses the blood-brain barrier, reaching steady-state CNS levels in 7-10 days.
Metabolism: Not metabolized; excreted unchanged.
Excretion: Renal elimination (95%) via glomerular filtration with 80% tubular reabsorption alongside sodium. Half-life is 18-24 hours in young adults, longer in elderly (up to 36 hours).
Key pharmacokinetic considerations
- Narrow therapeutic index: 0.6-1.2 mEq/L (maintenance); toxicity risk >1.5 mEq/L
- Steady state: achieved in 5-7 days
- Monitoring: serum levels drawn 12 hours post-dose (trough level)
- Renal function-dependent: dose adjustment required in renal impairment
- Sodium depletion increases lithium reabsorption, raising levels (risk with low-sodium diets, dehydration, diuretics)
Adverse effects
Common (dose-related)
- Fine tremor (most common; treat with dose reduction or propranolol)
- Gastrointestinal: nausea, diarrhea, abdominal discomfort
- Polyuria and polydipsia (nephrogenic diabetes insipidus in 20-40%)
- Weight gain (common, often significant)
- Cognitive dulling: difficulty concentrating, mental slowing
- Metallic taste
Endocrine
- Hypothyroidism (5-35%, more common in women): monitor TSH every 6-12 months
- Hyperparathyroidism and hypercalcemia (risk of nephrolithiasis)
- Rarely: goiter, hyperthyroidism
Renal
- Nephrogenic diabetes insipidus: impairs aquaporin-2 response to ADH; treat with amiloride or thiazides (paradoxical effect)
- Chronic tubulointerstitial nephropathy: with long-term use, may progress to chronic kidney disease
- Increased serum creatinine: monitor renal function regularly
Cardiac
- ECG changes: T-wave flattening or inversion (benign), rarely bradyarrhythmias
- Sinus node dysfunction in susceptible patients
Dermatologic
- Acne, psoriasis exacerbation, hair thinning
Neurologic
- Coarse tremor, ataxia, dysarthria: signs of toxicity
- Rarely: irreversible cerebellar syndrome with chronic toxicity
Lithium toxicity (>1.5 mEq/L): confusion, coarse tremor, hyperreflexia, ataxia, dysarthria, seizures, coma. Severe toxicity (>2.5 mEq/L) is life-threatening. Treatment includes intravenous fluids, hemodialysis for severe cases, and discontinuation of lithium.
Contraindications and warnings
Absolute contraindications
- Severe renal impairment (CrCl <30 mL/min)
- Severe cardiovascular disease or sick sinus syndrome
- Severe dehydration or sodium depletion
- Brugada syndrome (risk of unmasking)
Pregnancy and lactation
- Pregnancy category D (FDA, historical): risk of Ebstein anomaly (cardiac malformation, 0.05-0.1% vs 0.005% baseline), especially first trimester. Risk-benefit assessment required; consider alternatives when possible.
- Crosses placenta; neonatal risks include "floppy baby syndrome," nephrogenic diabetes insipidus, thyroid dysfunction
- Contraindicated in breastfeeding: excreted in breast milk at 30-100% of maternal serum levels
Warnings
- Black box warning: lithium toxicity closely related to serum levels; monitor carefully
- Dehydration, sodium depletion, or renal impairment increase toxicity risk
- Elderly patients require lower doses and more frequent monitoring
- Discontinuation should be gradual when possible (abrupt cessation increases relapse risk)
- Serotonin syndrome risk when combined with serotonergic agents
- Neurotoxicity risk with antipsychotics (especially haloperidol)
Drug interactions
Increased lithium levels (toxicity risk)
- Thiazide diuretics: decrease renal lithium clearance (most significant interaction)
- NSAIDs (except aspirin): reduce lithium excretion by 25-40%; celecoxib has lower risk
- ACE inhibitors and ARBs: reduce lithium clearance
- Loop diuretics: can cause volume depletion and compensatory proximal reabsorption, increasing lithium levels
- Metronidazole
Decreased lithium levels
- Osmotic diuretics (mannitol, urea): promote renal lithium excretion
- Theophylline, caffeine (increase renal clearance)
- Sodium bicarbonate, acetazolamide (alkalinize urine)
Pharmacodynamic interactions
- Serotonergic agents (SSRIs, SNRIs, MAOIs, triptans): serotonin syndrome risk
- Antipsychotics: increased neurotoxicity (confusion, extrapyramidal symptoms); risk higher with typical antipsychotics
- Carbamazepine: neurotoxicity risk
- Calcium channel blockers: bradycardia, neurotoxicity
- Methyldopa: increased risk of lithium toxicity symptoms
General precautions
Maintain stable sodium intake and hydration. Counsel patients to increase fluids during illness, exercise, or hot weather. Avoid starting NSAIDs without lithium level monitoring.
Clinical pearls
- Therapeutic drug monitoring is mandatory: check levels 12 hours post-dose, initially weekly until stable, then every 2-3 months. Also monitor renal function (creatinine, eGFR), TSH, calcium, and ECG at baseline and periodically.
- Lithium is renally eliminated unchanged; any factor affecting renal function or sodium balance impacts lithium levels. Dehydration is the most common precipitant of toxicity.
- Nephrogenic diabetes insipidus presents as polyuria (>3 L/day) and polydipsia. First-line management: once-daily dosing or amiloride. Thiazides paradoxically reduce urine volume but can increase lithium levels (requires dose adjustment).
- Tremor management: fine tremor is common and often dose-related. Propranolol 20-30 mg two to three times daily is effective. Coarse tremor suggests toxicity.
- Lithium has the strongest evidence for suicide prevention among mood stabilizers, making it particularly valuable in high-risk patients.
- Onset of antimanic effect: 7-14 days. Adjunctive antipsychotics or benzodiazepines often needed acutely.
- Toxicity without high levels: elderly patients or those with CNS disorders may develop neurotoxicity at therapeutic levels.
- Hemodialysis is effective for severe lithium toxicity because lithium is a small, unbound molecule. Rebound can occur as lithium redistributes from tissues; prolonged or repeat dialysis may be needed.
- Extended-release formulations reduce peak levels and may decrease GI side effects and tremor, but do not eliminate the need for monitoring.
- Pregnancy planning: if lithium is essential, avoid first trimester when possible. Fetal echocardiography at 16-18 weeks if exposure occurs. Consider dose reduction near term and post-delivery (fluid shifts alter levels).
LITHIUM toxicity signs: Lethargy, Irregular tremor (coarse), Tummy upset, Hyperreflexia, Increased confusion, Unsteady gait (ataxia), Muscle weakness
Practice questions
1. A 32-year-old woman with bipolar I disorder has been taking lithium 900 mg daily for 6 months with good symptom control. She presents to the emergency department with confusion, coarse tremor, and ataxia. Her serum lithium level is 2.1 mEq/L. She recently started a new medication for knee pain. Which medication most likely precipitated this presentation?
2. A 45-year-old man with bipolar disorder treated with lithium for 8 years presents with excessive thirst and urination (4-5 liters daily). His serum lithium level is 0.8 mEq/L (therapeutic). Laboratory studies show normal glucose, serum sodium 142 mEq/L, serum osmolality 290 mOsm/kg, and urine osmolality 150 mOsm/kg. Which mechanism best explains his symptoms?
3. A 28-year-old woman with bipolar disorder who is 8 weeks pregnant asks about continuing lithium therapy. She has had two severe manic episodes requiring hospitalization when off medication. Fetal ultrasound is scheduled for 18 weeks. Which statement regarding lithium use in pregnancy is most accurate?
Frequently asked questions
How does lithium work for bipolar disorder?
Lithium modulates intracellular signaling pathways, primarily by inhibiting inositol monophosphatase, which depletes phosphatidylinositol and dampens neuronal excitability. It also inhibits glycogen synthase kinase-3 (GSK-3), affects neurotransmitter systems (serotonin, dopamine, glutamate), and has neuroprotective effects. These pleiotropic mechanisms stabilize mood, reducing both manic and depressive episodes in bipolar disorder.
What are the common side effects of lithium?
Common side effects include fine hand tremor (most frequent), gastrointestinal upset (nausea, diarrhea), polyuria and polydipsia (nephrogenic diabetes insipidus), weight gain, cognitive dulling, and metallic taste. Endocrine effects include hypothyroidism (5-35%), hyperparathyroidism, and hypercalcemia. Dermatologic effects include acne and psoriasis exacerbation. Serious toxicity causes coarse tremor, confusion, ataxia, and seizures.
What is the therapeutic range for lithium?
The therapeutic range for lithium is 0.6-1.2 mEq/L for maintenance treatment, measured 12 hours after the last dose (trough level). For acute mania, levels up to 1.2 mEq/L may be targeted. Toxicity risk increases significantly above 1.5 mEq/L, with severe toxicity at >2.5 mEq/L. Regular monitoring is essential due to lithium's narrow therapeutic index and individual variability in response.
Can you take ibuprofen with lithium?
No, ibuprofen and other NSAIDs (except aspirin) should generally be avoided with lithium because they reduce renal lithium clearance, increasing serum levels by 25-40% and raising toxicity risk. If an NSAID is necessary, use the lowest effective dose for the shortest duration, increase monitoring of lithium levels, and consider dose adjustment. Acetaminophen (paracetamol) is a safer alternative for pain or fever.
Lithium vs valproate — what is the difference?
Lithium and valproate are both mood stabilizers for bipolar disorder, but differ in mechanisms, indications, and side effects. Lithium is more effective for classic euphoric mania and has superior evidence for suicide prevention, but has a narrow therapeutic index and requires regular monitoring. Valproate may be more effective for mixed episodes and rapid cycling, does not require level monitoring as strictly, but carries risks of hepatotoxicity, pancreatitis, and teratogenicity (neural tube defects). Choice depends on individual patient factors and bipolar subtype.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N05AN01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.